Literature DB >> 10745625

Protein expression and constitutive phosphorylation of hematopoietic transcription factors PU.1 and C/EBP beta in acute myeloid leukemia blasts.

H Iida1, M Towatari, M Iida, M Tanimoto, Y Kodera, A M Ford, H Saito.   

Abstract

The transcriptional activity of transcription factors is regulated by phosphorylation. The uncontrolled expression and constitutive activation of transcriptional regulators have been reported to cause malignant diseases. However, little is known about the phosphorylation status of tissue-specific transcription factors in human primary malignancies. Here we present the first insights into both protein expression and phosphorylation of transcription factors in a large-scale study of patients with acute myeloid leukemia (AML). We examined the expression and phosphorylation status of hematopoietic transcription factors PU.1 and C/EBP beta detected by the retarded mobility of the phosphorylated forms of the proteins. The rate of protein expression differed among French-American-British (FAB) subclasses. The expression of C/EBP beta and PU.1 were detectable in 77% and 61%, respectively, of 90 AML samples examined. The expressed PU.1 and C/EBP beta was always accompanied with both phosphorylated and unphosphorylated forms of PU.1 and C/EBP beta, respectively. Statistical significance was observed between PU.1 expression (phosphorylation) and FAB classification (M0, M4, or M5 versus M2 or M3, P < .0001). PU.1 and C/EBP beta were simultaneously detected in all M0, M4, M5 and peripheral blood monocytes, whereas in M2 and M3, the expression of the 2 transcription factors varied among samples. Examination of protein expression and phosphorylation of these lineage-specific molecules may help us to understand the functional characteristics of AML.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10745625

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  5 in total

1.  RUNX1 regulates corepressor interactions of PU.1.

Authors:  Zhenbo Hu; Xiaorong Gu; Kristine Baraoidan; Vinzon Ibanez; Arun Sharma; ShriHari Kadkol; Reinhold Munker; Steven Ackerman; Giuseppina Nucifora; Yogen Saunthararajah
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.

Authors:  Yogen Saunthararajah; Mikkael Sekeres; Anjali Advani; Reda Mahfouz; Lisa Durkin; Tomas Radivoyevitch; Ricki Englehaupt; Joy Juersivich; Kathleen Cooper; Holleh Husseinzadeh; Bartlomiej Przychodzen; Matthew Rump; Sean Hobson; Marc Earl; Ronald Sobecks; Robert Dean; Frederic Reu; Ramon Tiu; Betty Hamilton; Edward Copelan; Alan Lichtin; Eric Hsi; Matt Kalaycio; Jaroslaw Maciejewski
Journal:  J Clin Invest       Date:  2015-01-26       Impact factor: 14.808

3.  Trimming of mammalian transcriptional networks using network component analysis.

Authors:  Linh M Tran; Daniel R Hyduke; James C Liao
Journal:  BMC Bioinformatics       Date:  2010-10-13       Impact factor: 3.169

4.  Molecular characterisation of murine acute myeloid leukaemia induced by 56Fe ion and 137Cs gamma ray irradiation.

Authors:  Leta S Steffen; Jeffery W Bacher; Yuanlin Peng; Phuong N Le; Liang-Hao Ding; Paula C Genik; F Andrew Ray; Joel S Bedford; Christina M Fallgren; Susan M Bailey; Robert L Ullrich; Michael M Weil; Michael D Story
Journal:  Mutagenesis       Date:  2012-09-17       Impact factor: 3.000

5.  Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation.

Authors:  K P Ng; Z Hu; Q Ebrahem; S Negrotto; J Lausen; Y Saunthararajah
Journal:  Oncogenesis       Date:  2013-11-04       Impact factor: 7.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.